VIASURE™ CCHFV Real-Time PCR Kit

The VIASURE™ Crimean-Congo Haemorrhagic Fever Virus (CCHFV) Real-Time PCR Detection Kit is a molecular diagnostic assay designed for the qualitative detection of Crimean-Congo haemorrhagic fever virus RNA in human serum, whole blood, and other body fluids from patients with clinical signs and epidemiological risk factors consistent with CCHF infection.

This assay is intended to be used as an aid in the diagnosis of CCHF, in conjunction with clinical evaluation, patient history, and epidemiological exposure data, particularly during acute infection and outbreak situations.

Principle of the Test

The VIASURE™ CCHFV kit is based on real-time reverse transcription polymerase chain reaction (RT-RT-PCR) technology:

1. RNA Extraction
   Viral RNA is extracted from patient specimens using validated nucleic acid extraction methods.
2. Reverse Transcription & Amplification
   Extracted RNA is reverse-transcribed into complementary DNA (cDNA) and amplified using CCHFV-specific primers.
3. Fluorescent Detection
   Amplification is detected in real time using fluorescent reporter dye probes that are highly specific for the Crimean-Congo haemorrhagic fever virus genome.

The assay allows rapid, sensitive, and specific detection of CCHFV during the acute phase of infection, when viral RNA levels are highest.

Clinical Significance

Crimean-Congo haemorrhagic fever (CCHF) is a severe, tick-borne viral disease caused by a Nairovirus (family Bunyaviridae). The disease is associated with:

• Sudden onset of fever, myalgia, headache, and photophobia
• Gastrointestinal symptoms (nausea, vomiting, diarrhoea)
• Progression to haemorrhagic manifestations (petechiae, ecchymosis)
• Hepatic dysfunction, renal failure, and pulmonary failure in severe cases

The virus is primarily transmitted via Hyalomma ticks, infected livestock, and human-to-human contact through blood and body fluids, making it a significant public health threat, particularly in endemic and outbreak-prone regions.

Applications

• Clinical diagnosis of suspected CCHF cases
• Outbreak investigation and surveillance
• Public health reference laboratories
• Hospital and national virology laboratories
• Research on viral haemorrhagic fevers

Specimen Types

• Serum
• Whole blood
• Other body fluids

Performance & Methodology

• Method: Real-Time RT-PCR
• Target: Crimean-Congo haemorrhagic fever virus RNA
• Detection Phase: Acute phase of infection
• Result Type: Qualitative detection

Biosafety Considerations

• Testing of non-inactivated patient samples presents an extreme biohazard risk
• Testing should be performed only in maximum biological containment laboratories (BSL-3/4)
• Inactivated samples (e.g. treated with virucides, heat, gamma irradiation, or formaldehyde) may be processed in lower biosafety environments following institutional guidelines

Kit Stability & Storage

• Shelf Life: Up to 2 years from date of manufacture
• Storage & Transport: Room temperature
• Eliminates cold-chain dependency, ideal for resource-limited and field settings

Kit Formats & Ordering Information

Advantages

• High specificity for Crimean-Congo haemorrhagic fever virus
• Suitable for acute-phase diagnosis
• Room-temperature storage and transport
• Multiple formats for low-throughput to high-throughput laboratories
• Ideal for outbreak response and surveillance programs

The VIASURE™ CCHFV Real-Time PCR Detection Kit provides a robust, sensitive, and field-ready molecular solution for the detection of Crimean-Congo haemorrhagic fever virus. Its real-time PCR performance, flexible formats, and ambient storage conditions make it a valuable diagnostic tool for clinical laboratories, public health agencies, and outbreak response teams working to control and manage this high-risk viral disease.